…
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Mobia Medical, Inc. is a Nasdaq-listed company (MOBI) with limited publicly available detail on its core operations and revenue sources. Long-term growth would depend on successful commercialization of any medical products or services, regulatory approvals, and scaling of sales and reimbursement pathways. Investors may find potential upside if management clarifies strategy and achieves commercial traction.
The most important risks are limited public disclosure and unclear revenue visibility, potential need for additional financing, regulatory and execution uncertainty, and low liquidity that could magnify share price volatility.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 |
| Income before tax | -46.49M | -24.59M |
| Net income | -46.50M | -24.60M |
| Selling general administrative | 65.83M | 32.44M |
| Gross profit | 25.98M | 12.45M |
| Reconciled depreciation | 0.15M | 0.12M |
| Ebit | -45.53M | - |
| Ebitda | -45.37M | - |
| Depreciation and amortization | 0.15M | - |
| Operating income | -46.37M | -24.24M |
| Other operating expenses | 78.41M | - |
| Interest expense | 0.97M | 0.97M |
| Tax provision | 0.01M | 0.01M |
| Net interest income | -0.97M | -0.97M |
| Income tax expense | 0.01M | - |
| Total revenue | 32.04M | 15.64M |
| Total operating expenses | 72.34M | 39.88M |
| Cost of revenue | 6.07M | 3.19M |
| Total other income expense net | -0.12M | 0.62M |
| Net income from continuing ops | -46.50M | -24.60M |
| Breakdown | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 |
| Total assets | 48.15M | 22.09M |
| Other current assets | 2.88M | 0.30M |
| Total liab | 198.92M | 128.13M |
| Total stockholder equity | -150.77M | -106.04M |
| Other current liab | 7.63M | 0.50M |
| Common stock | 0.01M | - |
| Capital stock | 0.01M | 0.01M |
| Retained earnings | -157.79M | -111.29M |
| Cash | 33.59M | 14.62M |
| Total current liabilities | 10.21M | 4.60M |
| Net debt | -25.15M | - |
| Short term debt | 0.36M | - |
| Short long term debt total | 8.44M | - |
| Other stockholder equity | 7.01M | - |
| Total current assets | 46.36M | 21.17M |
| Net receivables | 4.44M | 2.83M |
| Long term debt | 7.13M | 7.09M |
| Inventory | 5.46M | 3.43M |
| Accounts payable | 2.22M | 1.14M |
| Non currrent assets other | 0.05M | 0.02M |
| Non current assets total | 1.79M | 0.92M |
| Capital lease obligations | 1.31M | 0.63M |
| Breakdown | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 |
| Total cashflows from investing activities | -0.36M | - |
| Total cash from financing activities | 65.03M | 15.66M |
| Net income | -46.50M | -24.60M |
| Change in cash | 18.97M | -8.70M |
| Begin period cash flow | 14.62M | 23.32M |
| End period cash flow | 33.59M | 14.62M |
| Total cash from operating activities | -45.69M | -24.32M |
| Issuance of capital stock | 64.71M | 14.99M |
| Depreciation | 0.15M | 0.12M |
| Change to inventory | -2.03M | -0.25M |
| Change to account receivables | -1.61M | -1.39M |
| Other cashflows from financing activities | 64.71M | - |
| Capital expenditures | 0.36M | 0.04M |
| Change in working capital | -0.92M | -0.63M |
| Stock based compensation | 1.45M | 0.76M |
| Other non cash items | 0.13M | 0.04M |
| Free cash flow | -46.06M | -24.36M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| MOBI Mobia Medical, Inc. Common Stock |
-0.01 0.08% |
11.85 | - | - | 7.92 | 1.94 | 3.65 |
| ABT Abbott Laboratories |
-0.20 0.19% |
103.00 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 |
| MDT Medtronic PLC |
-0.59 0.59% |
100.02 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 |
| SYK Stryker Corporation |
- -% |
310.00 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 |
| SEMHF Siemens Healthineers AG |
- -% |
48.34 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 |
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
| Name | Title | Year Born |
|---|---|---|
| Mr. Richard John Foust | CEO, President & Director | 1974 |
| Mr. Thomas Jordan Curnes II, M.B.A. | Co-Founder | 1979 |
| Mr. Nelson Bunker Curnes | Chief Financial Officer | 1983 |
| Mr. Prashant B. Rawat | Chief Operating Officer | 1974 |
| Mr. Douglas T. Ellison | Chief Commercial Officer | 1963 |
| Dr. Navzer Engineer M.D., Ph.D. | Co-Founder & Chief Scientific Officer | NA |
| Mr. Chase C. Leavitt J.D. | General Counsel & Corporate Secretary | 1982 |
| Mr. Philip B. Freed | Vice President of Marketing | NA |
| Ms. Steffanie Cook | Vice President of Human Resources | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.